A preliminary clinical report can document progress without settling whether an intervention works. This thymalfasin study should be read in that category. Primary study
Status at the reported cutoff
The 2023 publication described 194 hemodialysis patients randomized equally to thymalfasin or a no-thymalfasin control. It reported small interim numbers of deaths and COVID-19-related serious events. Most participants had received COVID-19 vaccination, with different counts between groups and vaccination occurring at varying times. Final antibody and efficacy analyses were still planned after follow-up completion. Primary report
Our appraisal: follow-up maturity changes interpretation
A count observed at an interim cutoff is not necessarily a completed risk estimate. Some participants may have had more observation time than others. A reliable comparison should define the time origin, exposure window, censoring rules, and completeness of follow-up before presenting a prevention percentage.
Vaccination is also time-dependent context, not simply a yes/no baseline label when it occurs during the study. Its timing can overlap the intervention and risk period. Any adjustment should follow a justified analysis plan; casually comparing vaccinated and unvaccinated subsets can introduce new selection problems.
With few events, even a visible numerical difference can be imprecise. Different outcomes, death, infection, hospitalization, or a serious-event category, should not be combined into a single efficacy claim unless the composite was defined and analyzed appropriately.
The publication's preliminary status is therefore part of the result, not a footnote to remove from a summary. A later complete report may clarify or change the interpretation and should be linked as a related version, not counted as independent replication. This record documents an early prevention-oriented trial report; it does not establish that thymalfasin prevents COVID-19 or improves survival in dialysis patients.
Frequently asked questions
Was this a final completed efficacy report?
No; it was explicitly preliminary.
Were participants receiving hemodialysis?
Yes.
Was allocation randomized?
The report describes equal randomization.
Were all participants vaccinated at the same time?
No.
Can raw interim counts establish a prevention percentage?
Not without the appropriate denominator and follow-up analysis.
Would a final report be an independent new trial?
No, if it reports the same participants.
What should a reader look for next?
Completed follow-up, prespecified efficacy analyses, and transparent safety reporting.